Wide Ranks

APRE

Aprea Therapeutics, Inc.

2.98

Top Statistics
Market Cap 16 M Forward PE -3.07 Revenue Growth 124.90 %
Current Ratio 9.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.3670 Enterprise / Revenue -4.07 Price To Sales Trailing12 Months 12.70
Profitability
Profit Margins 0.00 % Operating Margins -685.03 %
Balance Sheet
Total Cash 28 M Total Cash Per Share 5.28 Total Debt
Total Debt To Equity Current Ratio 9.55 Book Value Per Share 4.54
All Measures
Short Ratio 55.00 % Message Board Id finmb_329831339 Shares Short Prior Month 10410
Return On Equity -0.5011 City Doylestown Uuid 9a8f76c4-98d0-37f2-b77b-05a35baa6936
Previous Close 2.98 First Trade Date Epoch Utc 1 B Book Value 4.54
Beta 1.74 Volume 14996 Price To Book 0.6568
Last Split Date 1 B Fifty Two Week Low 2.15 Total Cash Per Share 5.28
Total Revenue 1 M Shares Short Previous Month Date 1 B Target Median Price 16.00
Audit Risk 8 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -685.03 % Target Mean Price 15.67 Net Income To Common -12927912
Short Percent Of Float 0.0038 Implied Shares Outstanding 5 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 10530 Average Volume10days 10530
Total Cash 28 M Next Fiscal Year End 1 B Revenue Per Share 0.2900
Held Percent Insiders 0.1175 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 2.98
Target Low Price 11.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.31
Open 2.76 Free Cashflow -9356979 State PA
Dividend Yield 0.00 % Return On Assets -0.3025 Time Zone Short Name EST
Board Risk 7 Trailing Eps -2.80 Day Low 2.71
Address1 3805 Old Easton Road Shares Outstanding 5 M Compensation Risk 9
Price Hint 4 Target High Price 20.00 Website https://www.aprea.com
52 Week Change -0.1813 Average Volume 22528 Forward Eps -1.02
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 927.40 %
Last Split Factor 1:20 Regular Market Day High 3.30 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 8.85 Day High 3.30
Shares Short 15177 Regular Market Open 2.76 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -4.07 Revenue Growth 124.90 %
Shares Percent Shares Out 0.0028 Operating Cashflow -13559135 Currency USD
Time Zone Full Name America/New_York Market Cap 16 M Is_nasdaq_100 False
Zip 18902 Quote Type EQUITY Industry Biotechnology
Long Name Aprea Therapeutics, Inc. Overall Risk 9 Regular Market Day Low 2.71
Held Percent Institutions 0.4385 Current Price 2.98 Enterprise To Ebitda 0.3670
Financial Currency USD Current Ratio 9.55 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 3 M
Two Hundred Day Average 4.50 Governance Epoch Date 1 B Enterprise Value -5196480
Price To Sales Trailing12 Months 12.70 Forward PE -3.07 Regular Market Volume 14996
Ebitda -14176494 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.

Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.

The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.

The company is headquartered in Doylestown, Pennsylvania.